Health Highlights: April 17, 2023
Therapeutic cancer vaccine boosts survival for people battling advanced melanoma. Each dose of the vaccine is crafted based on the unique genetics of the patient ’s cancer cells, and teaches the immune system to find and kill the cells. Read... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 17, 2023 Category: General Medicine Source Type: news
Personalized Cancer Vaccine Boosts Recurrence-Free Survival in Melanoma
(MedPage Today) -- ORLANDO -- Adding a personalized cancer vaccine to anti-PD-1 immunotherapy for resectable melanoma led to a 44% improvement in recurrence-free survival (RFS) versus immunotherapy alone, according to a study reported here.... (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - April 17, 2023 Category: Dermatology Source Type: news
Moderna and Merck Announce mRNA-4157 (V940), an Investigational Individualized Neoantigen Therapy, in Combination with KEYTRUDA(R) (Pembrolizumab), …
mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared to KEYTRUDA alone in stage III/IV melanoma patients with high risk of recurrence following complete resection Results from the Phase 2b KEYNOTE-942 trial selected for AACR press program Companies…#keytruda #cambridge #rahway #njaccesswire #rna #merck #msd #mrna4157p201 #mrna4157 #rfs (Source: Reuters: Health)
Source: Reuters: Health - April 17, 2023 Category: Consumer Health News Source Type: news
Skin cancer vaccine halved the risk of relapse in melanoma patients, research finds
Research demonstrates that an mRNA vaccine can successfully supplement treatment against cancer. (Source: Daily Express - Health)
Source: Daily Express - Health - April 16, 2023 Category: Consumer Health News Source Type: news
Moderna, Merck Show Progress Toward Cancer Vaccines
A Moderna and Merck trial offers some of the strongest evidence yet of vaccines that could benefit cancer patients. Moderna Inc. and Merck & Co.’s cancer vaccine helped prevent relapse for melanoma patients, results from a midstage trial showed, demonstrating progress in the pursuit of shots to…#moderna #merck #modernainc #merckcos (Source: Reuters: Health)
Source: Reuters: Health - April 16, 2023 Category: Consumer Health News Source Type: news
Roche ’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study
Discussions with health authorities are ongoing and follow-up will continue for the final RFS data and more mature OS data at the next planned analysis.The IMbrave050 study is part of Roche ’s overall commitment to drive fundamental treatment change and improve outcomes for people living with liver cancer. Tecentriq plus Avastin was the first treatment in over a decade to significantly improve OS over the existing standard of care, based on data from the IMbrave150 study.3 The Tecentriq combination quickly became a standard of care in unresectable HCC and is clearly defined as a preferred front-line treatment in multiple...
Source: Roche Media News - April 16, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study
Discussions with health authorities are ongoing and follow-up will continue for the final RFS data and more mature OS data at the next planned analysis.The IMbrave050 study is part of Roche ’s overall commitment to drive fundamental treatment change and improve outcomes for people living with liver cancer. Tecentriq plus Avastin was the first treatment in over a decade to significantly improve OS over the existing standard of care, based on data from the IMbrave150 study.3 The Tecentriq combination quickly became a standard of care in unresectable HCC and is clearly defined as a preferred front-line treatment in multiple...
Source: Roche Investor Update - April 16, 2023 Category: Pharmaceuticals Source Type: news
Why melanoma is so deadly for men, and why it doesn’t have to be
Men are much more likely to get skin cancer — and to die from it — than women. Here's what makes men so vulnerable to melanoma, the deadliest form of skin cancer. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - April 16, 2023 Category: Consumer Health News Authors: Andrea Atkins Source Type: news
Study Suggests Narrow Excision Margins Safe for Early Melanoma Study Suggests Narrow Excision Margins Safe for Early Melanoma
The results"support the need for prospective randomized clinical trials to definitively answer the important question about appropriate excision margins for T1a melanoma," the investigators write.MDedge News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 14, 2023 Category: Cancer & Oncology Tags: Dermatology News Source Type: news
Severe Colitis in Melanoma Patients Receiving BRAF/MEKi Severe Colitis in Melanoma Patients Receiving BRAF/MEKi
This report highlights the need to be aware of the possibility of severe colitis associated with BRAF/MEKi treatment for melanoma.Alimentary Pharmacology & Therapeutics (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 13, 2023 Category: Pathology Tags: Gastroenterology Journal Article Source Type: news
Sentinel Lymph Node Biopsy Guidelines in Melanoma Sentinel Lymph Node Biopsy Guidelines in Melanoma
Newly identified variables that may affect positivity rates for sentinel lymph node biopsies in melanoma may call for a redesign of current guidelines.ePlasty (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 13, 2023 Category: Pathology Tags: Plastic Surgery & Aesthetic Medicine Journal Article Source Type: news
Moderna Surges On A Key Win For Its Merck-Partnered Cancer Vaccine In Europe
stock climbed Monday after European regulators granted its Merck (MRK)-partnered personalized cancer vaccine a key designation. X Under the prime scheme designation, the European Medicines Agency gives early feedback on test results to speed up the development and evaluation of medicines that may…#merck #keytruda #melanoma #stephenhoge #ericrubin #moderna #marketsmithcom #allisongatlin #ibdagatlin (Source: Reuters: Health)
Source: Reuters: Health - April 10, 2023 Category: Consumer Health News Source Type: news
New therapy harnesses patients' blood cells to fight tumors
Adoptive cell therapy (ACT) has become a promising immunotherapy tool to help treat advanced melanoma. The therapy, which harnesses immune cells collected from the patient’s own tumors, could provide a new treatment option to cancer patients, potentially bypassing radiation therapies and harsh chemotherapy drugs. (Source: World Pharma News)
Source: World Pharma News - April 10, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
New therapy harnesses patients & #039; blood cells to fight tumors
Adoptive cell therapy (ACT) has become a promising immunotherapy tool to help treat advanced melanoma. The therapy, which harnesses immune cells collected from the patient’s own tumors, could provide a new treatment option to cancer patients, potentially bypassing radiation therapies and harsh chemotherapy drugs. (Source: World Pharma News)
Source: World Pharma News - April 10, 2023 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Update on IMBRUVICA ® (ibrutinib) U.S. Accelerated Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma Indications
HORSHAM, Pa., April 6, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with its alliance partner, Pharmacyclics, an AbbVie Company, announced today the intent to voluntarily withdraw the U.S. indications for IMBRUVICA® (ibrutinib) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy, and for the treatment of patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy. This decision was made in consultation with the U.S. Food and Drug Administration (FDA), c...
Source: Johnson and Johnson - April 6, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
